SCHEMBL11925241

SCHEMBL11925241

CC(C)NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.72
▸ KMT2A Q03164 2/20 0.72
▸ CYP3A4 P08684 2/20 0.72
▸ THRB P10828 2/20 0.72
▸ CHRM1 P11229 2/20 0.72
▸ MEN1 O00255 1/20 0.72
▸ ALOX15 P16050 1/20 0.72
▸ POLB P06746 1/20 0.72
▸ PKM P14618 1/20 0.72
▸ GRIA1 P42261 1/20 0.72
▸ GRIA2 P42262 1/20 0.72
▸ GRIA3 P42263 1/20 0.72
▸ RECQL P46063 1/20 0.72
▸ GRIA4 P48058 1/20 0.72
▸ BLM P54132 1/20 0.72
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA4 P22748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17471612 0.89 LMNA (0.76) LMNAKMT2ACYP3A4THRBCHRM1
Cyclothiazide SCHEMBL121096 0.84 LMNA (1.00) LMNAKMT2ACYP3A4THRBCHRM1
Cyclothiazide SCHEMBL22823942 0.84 LMNA (1.00) LMNAKMT2ACYP3A4THRBCHRM1
Cyclothiazide SCHEMBL1362539 0.84 LMNA (1.00) LMNAKMT2ACYP3A4THRBCHRM1
SCHEMBL22824000 0.80 LMNA (0.92) LMNAKMT2ACYP3A4THRBCHRM1
Cyclothiazide SCHEMBL21587525 0.80 LMNA (0.85) LMNAKMT2ACYP3A4THRBCHRM1
Cyclothiazide SCHEMBL28086372 0.79 LMNA (0.76) LMNAKMT2ACYP3A4THRBCHRM1
SCHEMBL19166751 0.78 LMNA (0.73) LMNAKMT2ACYP3A4THRBCHRM1
Cyclothiazide SCHEMBL28279779 0.76 LMNA (0.78) LMNAKMT2ACYP3A4THRBCHRM1
SCHEMBL11929014 0.75 LMNA (0.69) LMNAKMT2ACYP3A4THRBCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194732-A1 MULTI-API LOADING PRODRUGS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-07-12 — — US disclosed
US-20160024011-A1 Multi-API Loading Prodrugs ALKERMES PHARMA IRELAND LTD (IE) 2016-01-28 — — US disclosed
US-20120202823-A1 Multi-API Loading Prodrugs ALKERMES, INC. 2012-08-09 — — US disclosed
US-20120202823-A1 Multi-API Loading Prodrugs ALKERMES, INC. 2012-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024011-A1 Multi-API Loading Prodrugs AADAC, PAICS, ABCG2 LMNA 2855/4885KMT2A 652/4885CYP3A4 69/4885
US-20120202823-A1 Multi-API Loading Prodrugs AADAC, PAICS, ABCG2 LMNA 2855/4885KMT2A 652/4885CYP3A4 69/4885
US-20180194732-A1 MULTI-API LOADING PRODRUGS AADAC, PAICS, ABCG2 LMNA 2855/4885KMT2A 652/4885CYP3A4 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback